Your browser doesn't support javascript.
Severe SARS-CoV-2 patients develop a higher specific T-cell response.
Demaret, Julie; Lefèvre, Guillaume; Vuotto, Fanny; Trauet, Jacques; Duhamel, Alain; Labreuche, Julien; Varlet, Pauline; Dendooven, Arnaud; Stabler, Sarah; Gachet, Benoit; Bauer, Jules; Prevost, Brigitte; Bocket, Laurence; Alidjinou, Enagnon Kazali; Lambert, Marc; Yelnik, Cécile; Meresse, Bertrand; Dubuquoy, Laurent; Launay, David; Dubucquoi, Sylvain; Montaigne, David; Woitrain, Eloise; Maggiotto, François; Bou Saleh, Mohamed; Top, Isabelle; Elsermans, Vincent; Jeanpierre, Emmanuelle; Dupont, Annabelle; Susen, Sophie; Brousseau, Thierry; Poissy, Julien; Faure, Karine; Labalette, Myriam.
  • Demaret J; Institut d'Immunologie CHU de Lille Lille France.
  • Lefèvre G; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Vuotto F; Institut d'Immunologie CHU de Lille Lille France.
  • Trauet J; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Duhamel A; Service de Maladies Infectieuses CHU de Lille Lille France.
  • Labreuche J; Institut d'Immunologie CHU de Lille Lille France.
  • Varlet P; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Dendooven A; URL2694 Metrics: évaluation des technologies de santé et des pratiques médicales CHU de Lille Univ. Lille Lille France.
  • Stabler S; URL2694 Metrics: évaluation des technologies de santé et des pratiques médicales CHU de Lille Univ. Lille Lille France.
  • Gachet B; Institut d'Immunologie CHU de Lille Lille France.
  • Bauer J; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Prevost B; Institut d'Immunologie CHU de Lille Lille France.
  • Bocket L; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Alidjinou EK; Service de Maladies Infectieuses CHU de Lille Lille France.
  • Lambert M; U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille CNRS Inserm Institut Pasteur de Lille CHU de Lille Univ. Lille Lille France.
  • Yelnik C; Service de Maladies Infectieuses CHU de Lille Lille France.
  • Meresse B; Service de Maladies Infectieuses CHU de Lille Lille France.
  • Dubuquoy L; Laboratoire de Virologie EA3610 CHU de Lille Univ. Lille Lille France.
  • Launay D; Laboratoire de Virologie EA3610 CHU de Lille Univ. Lille Lille France.
  • Dubucquoi S; Laboratoire de Virologie EA3610 CHU de Lille Univ. Lille Lille France.
  • Montaigne D; Département de Médecine Interne et Immunologie Clinique Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO) CHU de Lille Lille France.
  • Woitrain E; U1167 Risk Factors and Molecular Determinants of Aging-Related Diseases Inserm CHU de Lille Univ. Lille Lille France.
  • Maggiotto F; Département de Médecine Interne et Immunologie Clinique Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO) CHU de Lille Lille France.
  • Bou Saleh M; U1167 Risk Factors and Molecular Determinants of Aging-Related Diseases Inserm CHU de Lille Univ. Lille Lille France.
  • Top I; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Elsermans V; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Jeanpierre E; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Dupont A; Département de Médecine Interne et Immunologie Clinique Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO) CHU de Lille Lille France.
  • Susen S; Institut d'Immunologie CHU de Lille Lille France.
  • Brousseau T; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
  • Poissy J; Department of Clinical Physiology & Echocardiography CHU de Lille Inserm U1011 - EGID Institut Pasteur de Lille Univ. Lille Lille France.
  • Faure K; Department of Clinical Physiology & Echocardiography CHU de Lille Inserm U1011 - EGID Institut Pasteur de Lille Univ. Lille Lille France.
  • Labalette M; U1286 - INFINITE - Institute for Translational Research in Inflammation Inserm CHU de Lille Univ. Lille Lille France.
Clin Transl Immunology ; 9(12): e1217, 2020.
Article in English | MEDLINE | ID: covidwho-985994
ABSTRACT

OBJECTIVES:

Assessment of the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for studying long-term immunity and vaccine strategies. We quantified IFNγ-secreting T cells reactive against the main viral SARS-CoV-2 antigens using a standardised enzyme-linked immunospot assay (ELISpot).

METHODS:

Overlapping peptide pools built from the sequences of M, N and S viral proteins and a mix (MNS) were used as antigens. Using IFNγ T-CoV-Spot assay, we assessed T-cell and antibody responses in mild, moderate and severe SARS-CoV-2 patients and in control samples collected before the outbreak.

RESULTS:

Specific T cells were assessed in 60 consecutive patients (mild, n = 26; moderate, n = 10; and severe patients, n = 24) during their follow-up (median time from symptom onset [interquartile range] 36 days [28;53]). T cells against M, N and S peptide pools were detected in n = 60 (100%), n = 56 (93.3%), n = 55 patients (91.7%), respectively. Using the MNS mix, IFNγ T-CoV-Spot assay showed a specificity of 96.7% (95% CI, 88.5-99.6%) and a specificity of 90.3% (75.2-98.0%). The frequency of reactive T cells observed with M, S and MNS mix pools correlated with severity and with levels of anti-S1 and anti-RBD serum antibodies.

CONCLUSION:

IFNγ T-CoV-Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long-lived memory T-cell response after vaccination. Our study demonstrates that SARS-CoV-2 patients developing a severe disease achieve a higher adaptive immune response.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Language: English Journal: Clin Transl Immunology Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Language: English Journal: Clin Transl Immunology Year: 2020 Document Type: Article